|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sotiriou C and Pusztai L: Gene-expression
signatures in breast cancer. N Engl J Med. 360:790–800. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Romond EH, Perez EA, Bryant J, Suman VJ,
Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman
PA, et al: Trastuzumab plus adjuvant chemotherapy for operable
HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carlson RW, Allred DC, Anderson BO,
Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ,
Gradishar WJ, et al: Breast cancer. Clinical practice guidelines in
oncology. J Natl Compr Canc Netw. 7:122–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rastelli F, Biancanelli S, Falzetta A,
Martignetti A, Casi C, Bascioni R, Giustini L and Crispino S:
Triple-negative breast cancer: Current state of the art. Tumori.
96:875–888. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee A and Djamgoz MBA: Triple negative
breast cancer: Emerging therapeutic modalities and novel
combination therapies. Cancer Treat Rev. 62:110–122. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kassam F, Enright K, Dent R, Dranitsaris
G, Myers J, Flynn C, Fralick M, Kumar R and Clemons M: Survival
outcomes for patients with metastatic triple-negative breast
cancer: Implications for clinical practice and trial design. Clin
Breast Cancer. 9:29–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watanabe-Fukunaga R, Iida S, Shimizu Y,
Nagata S and Fukunaga R: SEI family of nuclear factors regulates
p53-dependent transcriptional activation. Genes Cells. 10:851–860.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abdullah JM, Jing X, Spassov DS, Nachtman
RG and Jurecic R: Cloning and characterization of Hepp, a novel
gene expressed preferentially in hematopoietic progenitors and
mature blood cells. Blood Cells Mol Dis. 27:667–676. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hsu SI, Yang CM, Sim KG, Hentschel DM,
O'Leary E and Bonventre JV: TRIP-Br: A novel family of PHD zinc
finger- and bromodomain-interacting proteins that regulate the
transcriptional activity of E2F-1/DP-1. EMBO J. 20:2273–2285. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sugimoto M, Nakamura T, Ohtani N, Hampson
L, Hampson IN, Shimamoto A, Furuichi Y, Okumura K, Niwa S, Taya Y
and Hara E: Regulation of CDK4 activity by a novel CDK4-binding
protein, p34(SEI-1). Genes Dev. 13:3027–3033. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Calgaro S, Boube M, Cribbs DL and Bourbon
HM: The Drosophila gene taranis encodes a novel trithorax group
member potentially linked to the cell cycle regulatory apparatus.
Genetics. 160:547–560. 2002.PubMed/NCBI
|
|
14
|
Cheong JK, Gunaratnam L, Zang ZJ, Yang CM,
Sun X, Nasr SL, Sim KG, Peh BK, Rashid SB, Bonventre JV, et al:
TRIP-Br2 promotes oncogenesis in nude mice and is frequently
overexpressed in multiple human tumors. J Transl Med. 7:82009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hsieh JK, Yap D, O'Connor DJ, Fogal V,
Fallis L, Chan F, Zhong S and Lu X: Novel function of the cyclin A
binding site of E2F in regulating p53-induced apoptosis in response
to DNA damage. Mol Cell Biol. 22:78–93. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tategu M, Nakagawa H, Hayashi R and
Yoshida K: Transcriptional co-factor CDCA4 participates in the
regulation of JUN oncogene expression. Biochimie. 90:1515–1522.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Zhu G, Yang D, Li Q, Li Y, Xu X,
He D and Zeng C: The spindle function of CDCA4. Cell Motil
Cytoskeleton. 65:581–593. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shaul YD, Yuan B, Thiru P, Nutter-Upham A,
McCallum S, Lanzkron C, Bell GW and Sabatini DM: MERAV: A tool for
comparing gene expression across human tissues and cell types.
Nucleic Acids Res. 44:D560–D566. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lenz G: The RNA interference revolution.
Braz J Med Biol Res. 38:1749–1757. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu Y, Wu X, Li F, Huang D and Zhu W:
CDCA4, a downstream gene of the Nrf2 signaling pathway, regulates
cell proliferation and apoptosis in the MCF7/ADM human breast
cancer cell line. Mol Med Rep. 17:1507–1512. 2018.PubMed/NCBI
|
|
22
|
Kojima S and Borisy GG: An image-based,
dual fluorescence reporter assay to evaluate the efficacy of shRNA
for gene silencing at the single-cell level. F1000Res. 3:602014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alderman C, Sehlaoui A, Xiao Z and Yang Y:
MicroRNA-15a inhibits the growth and invasiveness of malignant
melanoma and directly targets on CDCA4 gene. Tumour Biol.
37:13941–13950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hayashi R, Goto Y, Ikeda R, Yokoyama KK
and Yoshida K: CDCA4 is an E2F transcription factor family-induced
nuclear factor that regulates E2F-dependent transcriptional
activation and cell proliferation. J Biol Chem. 281:35633–35648.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Phan NN, Wang CY, Li KL, Chen CF, Chiao
CC, Yu HG, Huang PL and Lin YC: Distinct expression of CDCA3,
CDCA5, and CDCA8 leads to shorter relapse free survival in breast
cancer patient. Oncotarget. 9:6977–6992. 2018. View Article : Google Scholar : PubMed/NCBI
|
